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Abstract 
 
Purpose 
We conducted a genome-wide association study to identify genetic factors that 
contribute to the etiology of phorias. 
 
Methods 
We measured near and far vertical and horizontal phorias in 988 healthy adults 
aged 16-40 using the Keystone Telebinocular with plates 5218 and 5219. We 
regressed degree of phoria against genotype at 642,758 genetic loci. To control 
for false positives we applied the conservative genome-wide permutation test to 
our data. 
 
Results 
A locus at 6p22.2 was found to be associated with the degree of near horizontal 
phoria (p = 2.3 x 10-8). The p-value resulting from a genome-wide permutation 
test was 0.014.  
 
Conclusions 
The strongest association signal arose from an intronic region of the gene 
ALDH5A1, which encodes the mitochondrial enzyme SSADH, an enzyme 
involved in GABA metabolism. SSADH deficiency, resulting from mutations of 
ALDH5A1, causes a variety of neural and behavioral abnormalities, including 
strabismus. Variation in ALDH5A1 is likely to contribute to degree of horizontal 
phoria.  
 
Introduction 
Heterophoria (phoria) is the degree to which the visual axes of the eyes deviate from 
concomitant alignment when there is no stimulus for binocular fusion. It reveals itself 
if binocular fusion is broken by covering one of the eyes or by presenting different 
stimuli to the two eyes. When a binocular target is present, heterophoria is overcome 
by vergence: The directions of gaze of the two eyes converge at the point of fixation. 
Heterophoria is distinguished from heterotropia, or strabismus, which is a manifest 
	   3	  
phoria, a persistent deviation of the axes of the eyes that cannot be eliminated by 
vergence. Though heterophorias and heterotropias are often discussed separately, they 
may share an underlying etiology. A popular idea is that heterotropia appears when 
for some reason the fusional mechanism fails.1 
 
The etiology of phorias is complex.1 They are thought to depend on a variety of 
anatomical and neural factors, including the anatomy of the bones, muscles and 
ligaments of the orbit, as well as neural signals sent to or from the extraocular 
muscles. Thus individual variability in phorias may plausibly arise from genetic 
differences that affect anatomical or neural factors.  
 
It has long been known that there are genetic factors in the etiology of strabismus.2,3 
Twin studies report heritabilities between about 50% and 100%.1 Wilmer and Backus4 
conducted a meta-analysis of twin studies of strabismus, and concluded that 
concordance for strabismus in monozygotic twins is at least three times higher than in 
dizygotic twins (53.8% vs. 13.8%). They estimated the heritability of strabismus to be 
92%. The heritability of phorias has not been so often studied. Wilmer and Backus4 
found high concordance for phoria in MZ twins (r = 0.58), but also found high 
concordance for DZ twins (r = 0.67). They concluded that variability in phorias, in 
contrast to strabismus, is not attributable to genetic factors, and that the concordance 
between twins can be completely explained by shared environment. In a later study, 
combining measurements of phoria and strabismus in 1,462 twin pairs, Sanfillippo et 
al.5 found that esodeviation (either esotropia or esophoria, a nasal deviation) is 
heritable at 64%, while exodeviation (a temporal deviation) is not. Though no genetic 
associations have been reported for phorias, several susceptibility loci6–8 and 
candidate genes9,10 have been suggested for strabismus.  
 
Most adults have a measureable phoria—a small exophoria on average.11 Orthophoria 
(where the visual axes are concomitantly aligned), is a minority phenotype. Because 
phoria is not pathological, it has not often been measured in clinical populations. 
However, manifest phoria (strabismus) has been reported to co-occur with many 
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clinical conditions including schizophrenia,12,13 mental retardation,14–16 Williams 
syndrome,17 Down’s Syndome,18,19 cerebral palsy,20 craniofacial dysostoses,21,22 
aniridia23 and congenital heart defects.24  Strabismus is also associated with prenatal 
environment: Prevalence is increased in children with fetal alcohol syndrome,25,26 or 
where the mother smoked during pregnancy.27  
 
Since phoria is a common trait amongst healthy adults, and since possible genetic 
influences on phorias are unknown, we included measurements of phorias in the 
PERGENIC genome-wide association study (GWAS). The PERGENIC study 
examined a range of sensory, perceptual and motor characteristics in a population of 
healthy adults aged 16-40.28,29  
 
Materials and methods 
Participants 
1060 (647 female) participants recruited from the Cambridge area were each paid £25 
to take part in our battery of 2.5 hours of psychophysical tests. A randomly selected 
105 participants returned for a second session at least a week after the first session, 
allowing us to measure test-retest reliability. To guard against population stratification 
in our sample, participants were all of self-reported European origin, and this was 
checked in the genomic analysis. Participants had a minimum visual acuity of 0.0 
LogMAR in at least one eye when corrected. 
 
The study was approved by the Cambridge Psychology Research Ethics Committee, 
and adhered to the tenets of the Declaration of Helsinki. All participants gave written 
informed consent before taking part. 
Measurement of phorias 
We used the commercially available Keystone telebinocular (Mast Concepts, Reno, 
Nevada, USA) with plates 5218 and 5219 to measure near (equivalent to 40 cm) and 
far (equivalent to 6 m) phorias respectively. These are combined plates for measuring 
both horizontal and vertical phorias, where a target consisting of a red vertical and a 
green horizontal line is presented to the left eye, and an oblique scale of numbered 
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points is presented to the right eye. On these Keystone combined plates a score of 3.5 
indicates orthophoria. One unit corresponds to one prism diopter for vertical phorias, 
and one unit corresponds to half a prism diopter for horizontal phorias. 
 
The red and green lines appear to intersect the scale at different places depending on 
the degree of phoria. On first viewing, the target lines often appeared to move relative 
to the scale. Participants were asked to report the numbered point of intersection for 
each target line, at the place where the target lines appeared to come to rest. The 
telebinocular test was administered by an experimenter about 30 minutes after the 
start of our 2.5-hour test battery. 
 
The Keystone telebinocular test of phorias is a quick and reliable method of 
measurement. It has been found to have comparable reliability to the clinical Maddox 
rod method of measuring phorias.30 The test does not distinguish phoria from manifest 
phoria (strabismus). 
 
Genetic methods 
Participants each provided 2 mL of saliva using Oragene OG-500 kits (DNA Genotek 
Inc, Ottawa, Canada). The saliva samples were stored at room temperature until data 
collection was complete. DNA was extracted from the saliva samples according to 
DNA Genotek protocols, and 1008 samples were genotyped by Cambridge Genomic 
Services (University of Cambridge, UK) using the HumanOmniExpress BeadChip 
(Illumina, San Diego, USA). The Illumina array characterized 733,202 SNPs from 
each sample. Genotype calling was by custom clustering, using Illumina 
GenomeStudio software. 
 
We excluded 20 individuals from our genetic data set. Three were excluded owing to 
sex anomalies, one owing to a low call rate, fifteen owing to relatedness or sample 
duplication and one for being a population outlier. The genetic data from 988 
participants were used in the GWAS. 
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Genotyped SNPs were excluded from the analysis if genotypes were missing for more 
than 2% of individuals (12,706 SNPs), or if the minor allele frequency was below 1% 
(77,738 SNPs). After excluding these 12.3% of the characterized SNPs, 642,758 
remained in the analysis.  
 
For each SNP we ran a linear regression model with our quantitative phenotype using 
the software PLINK.31 To control for any population stratification that remained in 
our sample, we used EIGENSOFT32 to extract the top three principal components 
(PC) accounting for genetic variation. The three PCs were entered, along with sex, as 
covariates in the regression. We performed genetic association analyses on four 
variables: Near and far vertical and horizontal phorias. 
 
Since our variables are not normally distributed, permutation analyses were run to 
control for type 1 errors. Phenotype–genotype correspondence in our data was 
randomly shuffled 10,000 times, and genetic associations were run for all SNPs in 
each permutation. To control for population stratification in the permutation analysis, 
we allowed shuffling of phenotypic data only within genetic clusters of participants. 
We identified clusters of genetically related individuals using PLINK’s clustering 
model with identity-by-state (IBS) as the distance metric. 
 
We carried out the permutation analyses using PLINK. The permuted p-value for each 
SNP is the proportion of permutations on which the test statistic for any SNP exceeds 
the test statistic found in the standard (unpermuted) association analysis for that 
particular SNP. These permutation analyses control for type 1 errors, because the null 
distribution of test statistics is accurately defined for the particular phenotypic data 
gathered. 
 
Loci that achieved a p-value of less than 0.05 in the permutation analyses were 
imputed over a region of 2.5 Mb surrounding the SNP of interest. We performed the 
imputation using the software IMPUTE233,34 with the 1000 genomes phased 
haplotypes.35 Association analyses of the imputed regions were carried out on the 
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genotype probabilities using the dosage association function of PLINK. The three PCs 
and sex were added into the analysis as covariates as in the initial stage.  
 
Finally, we performed a clumping analysis on our region of interest. We used 
PLINK’s clumping function, with a significance threshold for index SNPs of 0.00001, 
a significance threshold for clumped SNPs of 0.01, a linkage disequilibrium (LD) 
threshold for clumping of 0.1, and a physical distance threshold of 1250 kB. 
Clumping analysis defines a region that is in linkage disequilibrium with the 
significantly associated SNP, and which contains other SNPs also associated with the 
trait with a specified p-value. This region is therefore likely to contain the locus of 
interest, where the polymorphism causing the variation in phenotype lies. 
 
Results 
Test-retest reliabilities 
Test-retest reliabilities were based on 104 participants (data were unavailable for one 
returning participant). Reliabilities were high for the horizontal phorias (For far ρ = 
0.68, p = 2 x 10-15; for near ρ = 0.71, p < 10-16), and moderate for the vertical phorias 
(For far ρ = 0.56, p = 8 x 10-10; for near ρ = 0.54, p = 4 x 10-9).  Figure 1 shows plots 
of data from session 1 against data from session 2 for our 104 returning participants, 
for each of the four phorias we measured. Table 1 gives the alternative statistics of 
intra-class (C,1) correlation coefficients and Pearson’s correlation coefficients.  
 
Phenotypic distributions 
Distributions of phorias for our whole sample are shown in Figure 2. Data for 1057 of 
our 1060 participants were available. Standard deviations (in prism diopters) were 
5.32 for near horizontal phoria, 3.42 for far horizontal phoria, 0.791 for near vertical 
phoria and 0.698 for far vertical phoria.  
 
GWAS results 
Our criterion for deciding whether a SNP achieved genome-wide significance was 
that it should haves a permuted p-value of less than 0.05. One locus reached genome-
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wide significance for an association with near horizontal phoria. The locus contained 
three significantly associated SNPs: rs1569579, rs2744572 and rs807513, with 
unadjusted p-values of 2.3 x 10-8, 8.5 x 10-8 and 8.6 x 10-8 respectively. The permuted 
p-values were 0.014, 0.048 and 0.046. The p-value of the association with rs1569579 
meets the currently accepted threshold for modern assays36 (p < 5 x 10-8), and also 
survives a strict Bonferroni correction (α = 7.8 x 10-8).  
 
The linkage disequilibrium between rs1569579 and rs2744572 in our sample is r2 = 
0.88, calculated using PLINK, and the linkage disequilibrium between rs1569579 and 
rs807513 is r2 = 0.97. Figure 3 shows a whole-genome Manhattan diagram for near 
horizontal phorias. The significantly associated locus is in chromosomal region 6p22, 
and rs1569579 lies in the fifth intron of the gene ALDH5A1. There were 27 further 
SNPs associated with near horizontal phoria to a level of p < 10-7 in the region 1.25 
MB on either side of rs1569579. Figure 4 shows the associations between near 
horizontal phoria and genotyped and imputed SNPs in this region.  
 
The minor allele frequency of the lead SNP rs1569579 was 9% in our sample. Each 
additional copy of the C allele was associated with a shift in phoria of 0.45 standard 
deviations in the direction of esophoria. Variation at rs1569579 explains 3.2% of the 
total variance in near horizontal phoria. Figure 5 shows distributions of near 
horizontal phoria for participants homozygous for the major allele (TT), and for 
heterozygous participants (CT). Since there were only six participants homozygous 
for the minor allele (CC), they are not represented in this figure.  
 
Clumping analysis revealed a region spanning 159 kB associated with near horizontal 
phoria. This region contains the genes GPLD1, ALDH5A1, the last 10 exons of the 
gene MRS2 and the last 4 exons of the gene KIAA0319. 
 
Though no locus reached genome-wide significance for our three other measures of 
phoria (near and far vertical and far horizontal), the association between rs1569579 
and far horizontal phoria has a p-value of 8.1 x 10-5. This is to be expected, since near 
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and far horizontal phorias are related: They are significantly correlated in our sample 
(ρ = 0.584, p << 0.001). Because the two variables are significantly correlated, we 
also ran a multivariate genetic analysis including both horizontal and vertical 
phenotypes using TATES37. The probability returned by TATES that rs1569579 is 
associated with horizontal phoria was 4.1 x 10-8. Since near and far vertical phorias 
were also significantly correlated in our sample, we also conducted a multivariate 
analysis using TATES with these two phenotypes. No loci significantly associated 
with vertical phoria were identified by the TATES analysis.  
 
The association between rs1569579 and vertical phorias is very low (p = 0.76 for far 
vertical phoria and p = 0.59 for near vertical phoria). Again, this is not unexpected 
since the association between vertical and horizontal phorias is weak: In our sample, 
the correlations between vertical and horizontal phorias range from ρ = 0.089 (p = 
0.004) between far vertical and far horizontal phoria, to ρ = 0.01 (p = 0.75) between 
near vertical and near horizontal phoria.  
 
Interpupillary distance 
As part of the PERGENIC test battery we measured interpupillary distance by taking 
a photograph of the participants’ eyes using a digital camera (DS126191, Canon, 
Tokyo, Japan) mounted at a distance of 105 cm. The mean interpupillary distance was 
59.1mm (SD: 3.2mm; distance to point of fixation 100 cm). The test-retest reliability 
was 0.98, (p << 0.001). There was a weak but significant correlation between near 
horizontal phoria and interpupillary distance (ρ = 0.089, p = 0.0035). The association 
between our lead SNP for near horizontal phoria, rs1569579, and interpupillary 
distance had a p-value of 0.0007. These relationships are not unexpected, since 
manifest phoria (strabismus) must contribute some of the variance in interpupillary 
distance, and may thus contribute to the variance shared between our measure of near 
horizontal phoria and rs1569579.  
 
Discussion  
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In a genome-wide association study of phorias, we have identified one locus strongly 
associated with near horizontal phoria (p = 2.3 x 10-8; ppermuted = 0.014). The region 
containing the strongest association signal lies in the gene ALDH5A1. Independently, 
this gene is a very plausible candidate for being a source of variation in heterophoria 
and heterotropia.  
 
ALDH5A1 (aldehyde dehydrogenase 5 family, member A1) encodes a mitochondrial 
aldehyde dehydrogenase (NAD+)-dependent enzyme succinic semialdehyde 
dehydrogenase (SSADH). SSADH catalyses the oxidation of succinic semialdehyde 
to succinate, the last operation in degradation of GABA. ALDH5A1 has two major 
alternative transcripts, and a single promoter region.38 Blasi and colleagues have 
suggested that various missense mutations in ALDH5A1 may contribute to individual 
variability in SSADH activity. 
 
Mutations of ALDH5A1 cause the rare (and probably under-reported39) recessively 
inherited disorder succinic semialdehyde dehydrogenase deficiency, otherwise known 
as gamma-hydroxybutyric aciduria.40–44 In GABA degradation, without SSADH, 
transamination of GABA to succinic semialdehyde is followed by reduction to the 
neuropharmacologically active compound 4-hydroxybutyric acid (GHB). GHB is 
found normally as a minor metabolite of GABA, but builds up, with GABA, in the 
brains of those suffering from SSADH deficiency.  
 
The clinical features of SSADH deficiency include mental retardation, delayed 
language and motor development, hypotonia, seizures, behavioral problems, ataxia 
and hyporeflexia.45,46 Especially pertinent to the present study is the fact that SSADH 
deficiency has been associated with strabismus.45,46 However, owing to the rarity of 
SSADH deficiency (only a few hundred cases worldwide), most reports are of single 
cases or of a small number of cases. It is therefore difficult to assess accurately the 
incidence of strabismus in SSADH deficiency, especially since it may be omitted 
from case reports to give precedence to the more debilitating clinical features of the 
disorder.    
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Also linking ALDH5A1 to strabismus is valproic acid. Valproic acid is used as a drug 
to increase levels of GABA, probably by inhibiting SSADH.47,48 Exposure to valproic 
acid in utero causes fetal valproate syndrome, associated with a number of 
abnormalities, which include strabismus.49,50  
 
Aldh5a1 knockout mice have been studied as a model for SSADH deficiency. The 
mice show ataxia, seizures and failure to thrive. Seizures are lethal around post-natal 
day 25.51 The brains of the knockout mice have increased levels of GABA and 
decreased levels of glutamine,52 and show reduced expression and impaired function 
of GABA(A) and GABA(B) receptors,53 myelin abnormalities,54 and lipid 
abnormalities.55 Aldh5a1 knockout mice can be partially rescued by administration of 
vigabatrin, NCS382 (a GHB receptor antagonist), CHP 25348 (a GABA(B) receptor 
anatagonist), taurine, and a ketogenic diet.56  
 
Variation in ALDH5A1 has been associated with clinical conditions other than 
SSADH deficiency, including schizophrenia,57,58 mild developmental delay 
accompanied by increased SSADH activity59 and epilepsy,60,61 Variations in the gene 
ALDH5A1 in normal healthy adults have been associated with intelligence,62,63 and 
with cognitive functioning and survival in old age.64  
 
Though the pathway by which ALDH5A1 might influence ocular alignment is 
unclear, we can suggest one possibility. It has been suggested that one factor in the 
etiology of strabismus might be delayed myelination, causing early disturbance of 
oculomotor reflexes.65,66 Variation in ALDH5A1 may cause variation in myelination, 
since knockout mice have myelin abnormalities.  
 
The three other genes present in the region identified by clustering are MRS2, GPLD1 
and KIAA0319. MRS2 encodes a magnesium transporter protein thought to mediate 
the influx of magnesium ions into the mitochondrial matrix.67 GPLD1 encodes a 
phospholipase that leads to the release of proteins anchored by phosphatidylinositol 
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glycans from attachment to plasma membranes.68 Neither is an obvious candidate for 
variation in phorias. KIAA0319 encodes a transmembrane protein involved in 
neuronal migration during brain development.69 Its association with dyslexia has 
given it the alias Dyslexia Susceptibility 2 (DYLX2). KIAA0319 is associated with 
alterations in white matter: Knockdown mice have a reduction in the midsagittal area 
of the corpus callosum,70 and variation in KIAA0319 in humans is associated with 
variation in white matter volume in the temporo-parietal region.71 Since the 
innervation of ocular muscles might be a factor in the etiology of phorias, KIAA0319 
is also a plausible candidate for causing variation in phorias. We note that phoria and 
strabismus have sometimes been associated with dyslexia,70 and dyslexia has been 
controversially treated using prisms.71 However, there are also reports that dyslexia is 
not associated with the presence of binocular abnormalities.74,75 
 
Phoria and strabismus 
Combining their own measurements of phorias in twins with a meta-analysis of 
previous studies of strabismus in twins, Wilmer and Backus4 made the interesting 
suggestion that phorias are not heritable whereas strabismus is. Could the presence of 
a small number of strabismics in our population be driving the association we report 
here? We think this is unlikely for two reasons. First, Figure 5 shows that the 
difference in phoria by genotype does not depend upon a few outliers, but reveals 
itself in a shift of the entire distribution. Second, following Wilmer and Backus 
(2011), we took failure on the TNO test (stereo-acuity worse than 480 arcseconds) as 
an (over-conservative) surrogate indicator of strabismus, and re-analysed our data 
eliminating such participants (n = 94). We found only a modest increase in the p-
value for the association between near horizontal phoria and rs1569579 to 7.7x10-8, 
an increase consistent with the reduction in the number of participants entered into the 
analysis.  
 
In fact, our genetic association is not incompatible with Wilmer and Backus’ negative 
finding in their twin study of heritability of phoria. The error bars on their correlation 
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coefficients for the concordance of monozygotic twin pairs and of dizygotic twin 
pairs are compatible with the 3.2% genetic effect that we find here.  
 
Conclusions 
In conclusion, our results indicate that a locus in 6p22.2 is associated with near 
horizontal phoria. The most strongly associated variant is in the gene ALDH5A1. 
Though the effect size is large by GWAS standards, it is likely to be inflated to some 
degree by the winner’s curse76, and this should be considered for future replication 
designs. Independent replication would be a vital next step, with exploration of the 
biological pathway by which ALDH5A1 may exert its effect on phoria.  
 
Given the occurrence of ocular deviation in a range of neuropsychiatric conditions, 
phorias may prove useful as a relatively easily measured endophenotype:	  Elucidating 
their genetic basis may provide a clue to the basis of more complex phenotypes.    
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Figure and Table Legends 
Table 1. Test-retest reliabilities for the four measures of phoria. We consider 
Spearman’s rho to be the most suitable measure of reliability since the 
distributions of phorias in our sample are not normal. N = 104.  
 
Figure 1. Scatter plots showing the test-retest reliabilities for horizontal and 
vertical near and far phorias. For each data point, the area of the marker is 
proportional to the number of participants sharing that point. The grey line is 
the orthogonal linear regression to the data. The Spearman coefficients for the 
correlation between session 1 phorias and session 2 phorias are 0.71 for far 
horizontal, 0.68 for near horizontal, 0.56 for far vertical and 0.54 for near 
vertical. 
 
Figure 2. Distributions of near and far vertical and horizontal phorias for our 
1057 participants 
 
Figure 3. Manhattan diagram for near horizontal phorias. A locus on 
chromosome six reached genome-wide significance. The figure shows genotyped 
SNPs only, not imputed SNPs.  
 
Figure 4. Manhattan diagram for the region around rs1569579. (Top) 
Association results for genotyped SNPs (red diamonds with black borders) and 
imputed SNPs (red diamonds with saturation corresponding to imputation 
quality). Recombination rate is plotted with a solid blue line. (Bottom) The 
genomic context of the region. Vertical rectangles indicate exons. (Both) Vertical 
blue dashed lines illustrate the region identified by clustering in which the 
underlying genetic polymorphism is likely to lie.  
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Figure 5. Distributions of near horizontal phorias for participants with different 
genotypes at rs1569579. Heterozygotes (TC) are indicated by the dashed line and 
homozygotes (TT) are indicated by the solid line. Each additional copy of the C 
allele shifts phoria by 0.45 standard deviations in the direction of esophoria.	  
